Medivir AB announced the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with L envima®? in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks.

The data update will be part of Medivir's interim report for the third quarter on October 27, 2023, followed by a comprehensive update in a webcasted presentation with associated slide presentation at 14.00 CET the same day. In the webcast, Medivir will provide further context about how these data increase the opportunity for fostrox + L envima®? to transform treatment of second line HCC, a population for whom there are no approved medical treatments post current standard of care.

In addition, the company will outline how promising clinical benefit in a high unmet medical need second line HCC population, opens the possibility for a faster path to approval and its commercial opportunity.